Rituximab in the treatment of nephrotic syndrome: A systematic review

Otukesh, H. and Hoseini, R. and Rahimzadeh, N. and Fazel, M. (2013) Rituximab in the treatment of nephrotic syndrome: A systematic review. Iranian Journal of Kidney Diseases, 7 (4). pp. 249-256.

Full text not available from this repository.
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....


Recently, the role of B cells in the pathogenesis of nephritic syndrome is explained by some researchers. It has also been shown that the anti-CD20 antibody, rituximab, may be an option in the treatment of these patients. In this systematic review, we performed extensive search and identified studies on rituximab use in children with nephrotic syndrome. There are some case reports as well as larger series in this regard. The majority of these case reports and series have demonstrated the success of rituximab in the treatment of nephrotic syndrome, especially in pediatric patients with steroid-dependent and frequent-relapsing nephrotic syndrome. Nevertheless, the treatment strategies before and after rituximab infusion are not clear to date. On the other hand, it is believed that positive results on rituximab use in nephrotic syndrome are much more reported by researchers than the negative results and this is an important bias. Although most reports on rituximab use in pediatric patients have not recognized significant side effects, the long-term adverse events of rituximab are not known. Thus, controlled long-term studies are required to be done to assess the risk-benefit profile of rituximab in childhood nephrotic syndrome.

Item Type: Article
Additional Information: cited By 3
Uncontrolled Keywords: calcineurin; calcineurin inhibitor; cotrimoxazole; cyclophosphamide; cyclosporin; levamisole; mycophenolic acid 2 morpholinoethyl ester; prednisolone; rituximab; steroid; tacrolimus, adult respiratory distress syndrome; anaphylaxis; article; bronchospasm; cell count; chill; congenital nephrotic syndrome; disease control; drug dose comparison; drug efficacy; drug eruption; drug fever; drug treatment failure; frequent relapsing nephrotic syndrome; hormone dependence; human; humoral immune deficiency; hypotension; immunoglobulin deficiency; infusion related reaction; injection site infection; interstitial pneumonia; loading drug dose; long term care; low drug dose; lung fibrosis; maintenance therapy; memory cell; monotherapy; multiple cycle treatment; nephrotic syndrome; Pneumocystis carinii; pneumocystosis; progressive multifocal leukoencephalopathy; proteinuria; randomized controlled trial (topic); recommended drug dose; recurrent disease; risk benefit analysis; single drug dose; steroid dependent nephrotic syndrome; steroid therapy; systematic review; treatment duration; treatment outcome; ulcerative colitis
Subjects: WJ Urogenital System
Depositing User: somayeh pourmorteza
Date Deposited: 19 May 2019 06:38
Last Modified: 19 May 2019 06:38
URI: http://eprints.iums.ac.ir/id/eprint/9673

Actions (login required)

View Item View Item